Table 2.
Average patient age, average disease-free survival (DFS), and mutation frequency in breast cancer subtypes with or without mutations
| Subtype | n (% total) | Average age (years) | Average DFS (months) | Samples with mutations (freq.) | Samples without mutations (freq.) | Average age with mutations (years) | Average age without mutations (months) | P value | Average DFS with mutations (months) | Average DFS without mutations (months) | P value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| All | 80 (100%) | 54.5 | 38.3 | 32 (40.0%) | 48 (60.0%) | 54.9 | 54.2 | 0.757 | 38.8 | 38.0 | 0.741 |
| Luminal A | 21 (26.3%) | 53.7 | 39.0 | 9 (42.9%) | 12 (57.1%) | 53.8 | 53.7 | 0.979 | 40.6 | 37.8 | 0.407 |
| Luminal B/HER2− | 17 (21.3%) | 55.8 | 39.4 | 6 (35.3%) | 11 (64.7%) | 57.3 | 54.9 | 0.626 | 40.5 | 38.7 | 0.799 |
| Luminal B/HER2+ | 24 (30.0%) | 52.9 | 37.3 | 11 (45.8%) | 13 (54.2%) | 53.6 | 52.3 | 0.772 | 37.5 | 37.1 | 0.936 |
| Triple negative | 6 (7.5%) | 53.8 | 37.5 | 4 (66.7%) | 2 (33.3%) | 58.8 | 44.0 | 0.165 | 39.8 | 33.0 | 0.508 |
| HER2 overexpressing | 7 (8.8%) | 56.6 | 34.6 | 2 (28.6%) | 5 (71.4%) | 52.5 | 58.2 | 0.633 | 31.5 | 35.8 | 0.595 |
| Unknown | 5 (6.3%) | 59.0 | 43.0 | 0 (0.0%) | 5 (100%) | - | 59.0 | - | - | 43.0 | - |